TRMED Thor Medical ASA
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It offers thorium-228, as well as radium-224 and lead-212 to radiopharmaceutical customers. The company was incorporated in 2009 and is headquartered in Oslo, Norway.…
Industry Peers
BiotechnologyKey Statistics
About Thor Medical (OSL: TRMED)
›
Thor Medical (OSL: TRMED) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 24 employees.
The shares were at 3.990 NOK on 19 November 2026, up 7.8% over 52 weeks. Its 52-week range is 3.485 NOK to 7.120 NOK: the price is 44.0% below the high and 14.5% above the low.
Its market capitalisation is 1.69B NOK.
Thor Medical reports return on equity of -12.7% and revenue up 800.0% year over year.
Its debt exceeds its cash by 182.30M NOK, a debt-to-equity ratio of 0.38. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 2 analysts cover the stock; their mean price target of 5.600 NOK is 40.4% above the current price. The next earnings report is expected on 25 February 2027.